Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
66.6M
-
Number of holders
-
83
-
Total 13F shares, excl. options
-
12.8M
-
Shares change
-
-436K
-
Total reported value, excl. options
-
$34.1M
-
Value change
-
-$900K
-
Put/Call ratio
-
0.11
-
Number of buys
-
32
-
Number of sells
-
-38
-
Price
-
$2.67
Significant Holders of Cardiff Oncology, Inc. - Common Stock (CRDF) as of Q3 2024
104 filings reported holding CRDF - Cardiff Oncology, Inc. - Common Stock as of Q3 2024.
Cardiff Oncology, Inc. - Common Stock (CRDF) has 83 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 12.8M shares
of 66.6M outstanding shares and own 19.17% of the company stock.
Largest 10 shareholders include BlackRock, Inc. (2.74M shares), VANGUARD GROUP INC (2.17M shares), GEODE CAPITAL MANAGEMENT, LLC (928K shares), STATE STREET CORP (833K shares), MAI Capital Management (663K shares), RENAISSANCE TECHNOLOGIES LLC (602K shares), MORGAN STANLEY (498K shares), Nuveen Asset Management, LLC (338K shares), TWO SIGMA ADVISERS, LP (331K shares), and NORTHERN TRUST CORP (310K shares).
This table shows the top 83 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.